Department of Surgery

Medicine & Life Sciences

1. Adenocarcinoma 8%
2. Adjuvant Chemotherapy 8%
3. alpha-Fetoproteins 7%
4. Appendectomy 9%
5. Bile Duct Neoplasms 10%
6. Bile Ducts 13%
7. Biliary Tract Neoplasms 6%
8. Biomarkers 8%
9. Biopsy 8%
10. Body Mass Index 8%
11. Breast 42%
12. Breast Neoplasms 100%
13. Carcinoma 9%
14. Cell Line 7%
15. Colitis 7%
16. Colonic Neoplasms 19%
17. Colorectal Neoplasms 27%
18. Common Bile Duct 17%
19. Confidence Intervals 11%
20. Databases 7%
21. Disease-Free Survival 9%
22. Drug Therapy 12%
23. Ductal Carcinoma 9%
24. Epithelial-Mesenchymal Transition 11%
25. Estrogen Receptors 15%
26. Familial Breast Cancer 7%
27. Fluorodeoxyglucose F18 10%
28. Graves Disease 10%
29. Hemorrhoids 7%
30. Hepatectomy 10%
31. Hepatocellular Carcinoma 15%
32. Hormones 12%
33. human ERBB2 protein 10%
34. Incidence 7%
35. Indocyanine Green 9%
36. Intussusception 7%
37. Kidney 9%
38. Kidney Transplantation 10%
39. Laparoscopic Cholecystectomy 12%
40. Laparoscopy 11%
41. Length of Stay 8%
42. Letrozole 8%
43. Ligation 7%
44. Liver 21%
45. Liver Transplantation 54%
46. Living Donors 45%
47. Lymph Node Excision 7%
48. Lymph Nodes 19%
49. Mammaplasty 7%
50. Margins of Excision 8%
51. Mastectomy 15%
52. Matrix Metalloproteinase 7 6%
53. Meta-Analysis 7%
54. Microbiota 6%
55. Multicenter Studies 15%
56. Multivariate Analysis 7%
57. Mutation 11%
58. Neoplasm Metastasis 28%
59. Neoplasms 35%
60. Neuroendocrine Tumors 8%
61. Nipples 9%
62. Odds Ratio 9%
63. Organ Transplantation 8%
64. Ovarian Neoplasms 7%
65. Pain 6%
66. Pancreatectomy 11%
67. Pancreatic Neoplasms 8%
68. Pancreaticoduodenectomy 12%
69. Papillary Thyroid Cancer 30%
70. Postoperative Complications 10%
71. Postoperative Pain 11%
72. Propensity Score 15%
73. Randomized Controlled Trials 8%
74. Reactive Oxygen Species 8%
75. Rectal Neoplasms 19%
76. Recurrence 39%
77. Registries 19%
78. Regulatory T-Lymphocytes 20%
79. Retrospective Studies 11%
80. Robotics 40%
81. Safety 21%
82. Segmental Mastectomy 13%
83. Sentinel Lymph Node Biopsy 9%
84. Serum 9%
85. Stomach Neoplasms 18%
86. Surgeons 6%
87. Survival 23%
88. Survival Rate 18%
89. Tacrolimus 9%
90. Tamoxifen 10%
91. Therapeutics 15%
92. Thyroid Gland 11%
93. Thyroid Neoplasms 14%
94. Thyroidectomy 44%
95. Tissue Donors 26%
96. Transforming Growth Factors 9%
97. Transplant Recipients 7%
98. Transplantation 7%
99. Transplants 15%
100. Triple Negative Breast Neoplasms 22%